Pharmaceutical companies are developing new drugs in only two symphoms areas these days — cancer and rare diseases. These are the only therapeutic areas where exorbitant pricing is tolerated by payers. How exorbitant are we talking about? And prices continue to soar. Who loses from this pricing practice? You might think the patients with cancer or with rare diseases are most likely to suffer. But that isn’t pharmaceutucal. To cover these exorbitant costs for even a small pharmaceutical companies make money on treating symptoms of people, payers slash their expenditures in other therapeutic areas, and these cuts affect millions of people. Physicians are not good at challenging payers, so most patients will get the second-rate treatment. So the patients who lose the most are typically those who do not have cancer or rare diseases. Actually, nearly everyone else loses when a company prices a novel drug at extreme levels. According to an article by Tae Kim on CNBCGoldman Sachs i...